Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Moore

Showing results (1291-1300 of 1,421) with videos related to

Pageof 143
Sort By:
Gynecologic Oncology|November 12, 2019
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancerKathleen N Moore, Austin Miller, Katherine M Bell-McGuinn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 26, 2017
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factorsJ McGee, M Bookman, P Harter, et al.
Molecular Cancer Therapeutics|July 24, 2023
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and LymphomaErika P Hamilton, Judy S Wang, Amit M Oza, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2016
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancerShubham Pant, Suzanne F Jones, Carla D Kurkjian, et al.
Gynecologic Oncology|September 22, 2016
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice GuidelineAlexi A Wright, Kari Bohlke, Deborah K Armstrong, et al.
Gynecologic Oncology|September 23, 2017
Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group studyKathleen N Moore, David Tritchler, Kenneth M Kaufman, et al.
The Journal of Organic Chemistry|March 29, 2013
Stereospecific Suzuki, Sonogashira, and Negishi coupling reactions of N-alkoxyimidoyl iodides and bromidesDebra D Dolliver, Bijay T Bhattarai, Arjun Pandey, et al.
Science Signaling|July 28, 2021
Short stature and combined immunodeficiency associated with mutations in RGS10Ivan K Chinn, Zhihui Xie, Eunice C Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2016
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice GuidelineAlexi A Wright, Kari Bohlke, Deborah K Armstrong, et al.
Gynecologic Oncology|March 26, 2017
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group studyDanielle A Jandial, William E Brady, Stephen B Howell, et al.
Pageof 143

Showing results (1291-1300 of 1,421) with videos related to

Sort By:
Pageof 143
Gynecologic Oncology|November 12, 2019
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancerKathleen N Moore, Austin Miller, Katherine M Bell-McGuinn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 26, 2017
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factorsJ McGee, M Bookman, P Harter, et al.
Molecular Cancer Therapeutics|July 24, 2023
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and LymphomaErika P Hamilton, Judy S Wang, Amit M Oza, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2016
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancerShubham Pant, Suzanne F Jones, Carla D Kurkjian, et al.
Gynecologic Oncology|September 22, 2016
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice GuidelineAlexi A Wright, Kari Bohlke, Deborah K Armstrong, et al.
Gynecologic Oncology|September 23, 2017
Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group studyKathleen N Moore, David Tritchler, Kenneth M Kaufman, et al.
The Journal of Organic Chemistry|March 29, 2013
Stereospecific Suzuki, Sonogashira, and Negishi coupling reactions of N-alkoxyimidoyl iodides and bromidesDebra D Dolliver, Bijay T Bhattarai, Arjun Pandey, et al.
Science Signaling|July 28, 2021
Short stature and combined immunodeficiency associated with mutations in RGS10Ivan K Chinn, Zhihui Xie, Eunice C Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2016
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice GuidelineAlexi A Wright, Kari Bohlke, Deborah K Armstrong, et al.
Gynecologic Oncology|March 26, 2017
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group studyDanielle A Jandial, William E Brady, Stephen B Howell, et al.
Pageof 143